Hollis Eden Pharmaceuticals Inc. (HEPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Hollis Eden Pharmaceuticals Inc. (HEPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Tom Ronk who wrote (135)	5/31/2005 12:49:42 PM
From: Jim Oravetz	Read Replies (1) of 138

Hollis-Eden Announces Filing Of An IND For NEUMUNE In The US DOW JONES NEWSWIRES May 31, 2005 7:48 a.m. SAN DIEGO -- Hollis-Eden Pharmaceuticals Inc. (HEPH) filed for regulatory approval to start clinical trials in the U.S. for a radiation treatment, which the company hopes to sell to the federal government's ProjectBioShield program. In a press release Tuesday, the San Diego biopharmaceutical company said it filed an investigational new drug application with the Food and Drug Administration to start a Phase I clinical trial in the U.S. for its Neumune drug to treat patients exposed to high doses of radiation. The company is already conducting a Phase I trial in the Netherlands. Hollis-Eden's Neumune is eligible for FDA marketing approval based on efficacy tests only on animals and not humans, since testing radiation on humans has been deemed unethical. The company is trying to win an advance purchase contract from the U.S. government to provide Neumune to the strategic national stockpile. Hollis-Eden has filed a related request for information with ProjectBioShield. Company Web site: holliseden.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next